{
    "clinical_study": {
        "@rank": "42043", 
        "arm_group": [
            {
                "arm_group_label": "Tablet formulation", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Capsule formulation", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be a Phase 1, open-label, randomized, 2-period, 2-treatment sequ ence\n      crossover study to determine the relative bioavailability of cobimetinib ad ministered as a\n      single dose of the tablet formulation relative to a single dose of the capsule formulation\n      to healthy male and female participants. A minimum of 24 participants (12 participants per\n      sequence) will complete the study. Partici pants will be randomly assigned to 2 possible\n      sequences (i.e., I: A/B, II: B/A) where the treatments are as follows: Treatment A: One\n      cobimetinib tablet adminis tered as a single oral dose after at least an 8-hour fast;\n      Treatment B: Four cob imetinib capsules administered as a single oral dose after at least an\n      8-hour fa st. The study is expected to last approximately 7 weeks."
        }, 
        "brief_title": "A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers between 18 and 55 years of age, inclusive\n\n          -  Body mass index between 18.5 to 32.0 kg/m2, inclusive;\n\n          -  Adequate renal, liver, and hematologic function\n\n          -  Participants who are in good health as determined by no clinically significant\n             findings from medical history, 12-lead ECG, vital signs, and clinical laboratory\n             evaluations\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,\n             gastrointestinal, neurological, or psychiatric disorder (as determined by the\n             Investigator)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136524", 
            "org_study_id": "GP28370"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tablet formulation", 
                "description": "Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast", 
                "intervention_name": "cobimetinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Capsule formulation", 
                "description": "Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast", 
                "intervention_name": "cobimetinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE 1, OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, 2-PERIOD, 2-TREATMENT SEQUENCE CROSS-OVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF COBIMETINIB ADMINISTERED AS A TABLET FORMULATION COMPARED TO A CAPSULE FORMULATION IN HEALTHY SUBJECTS", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Time to maximum concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Apparent terminal elimination rate constant", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Apparent clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }, 
            {
                "measure": "Relative bioavailability (Frel)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 weeks"
        }, 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}